---
schema_version: "secwatch.filing_event.v1"
accession: "0001576280-23-000005"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:49:59.850465+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Guardant Health prelim FY22 revenue $447-450M, up 20%; test volumes up >40% YoY

## Summary
- Preliminary FY22 revenue $447M-$450M, up 20% YoY; Q4 revenue $124M-$127M, up 15-17%.
- FY22 clinical test volumes 124,800 (+42% YoY); biopharma tests 26,000 (+40% YoY).
- Q4 clinical tests 36,000 (+41% YoY); biopharma tests 8,200 (+24% YoY).
- Cash, equivalents and marketable debt securities $1.0B as of Dec 31, 2022.
- Positive ECLIPSE trial readout for Shield blood-based colorectal cancer test; expanding to lung cancer.

## SEC filing metadata
- accession: 0001576280-23-000005
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000157628023000005/0001576280-23-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000157628023000005/gh-20230109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576280-23-000005
- JSON: https://secwatch.observer/filing/0001576280-23-000005.json
- Plain text: https://secwatch.observer/filing/0001576280-23-000005.txt

## Key facts
- Earnings Releases
  Guardant Health, Inc. reported the year ended December 31, 2022 results: revenue between $447 million and $450 million.
  - Period: the year ended December 31, 2022
  - Revenue: between $447 million and $450 million
  - Result: preliminary results
  source text: Full year 2022 preliminary unaudited financial results For the twelve-month period ended December 31, 2022, as compared to the same period of 2021: • Revenue of between $447 million and $450 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000157628023000005/0001576280-23-000005-index.htm
- Earnings Releases
  Guardant Health, Inc. reported the quarter ended December 31, 2022 results: revenue between $124 million and $127 million.
  - Period: the quarter ended December 31, 2022
  - Revenue: between $124 million and $127 million
  - Result: preliminary results
  source text: Fourth quarter 2022 preliminary unaudited financial results For the three-month period ended December 31, 2022, as compared to the same period of 2021: • Revenue of between $124 million and $127 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000157628023000005/0001576280-23-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.